Zydus Cadila gets US FDA nod to market anti-depressant drug
Drug firm Zydus Cadila has received final approval from the US health regulator to market Amitriptyline hydrochloride tablets used for treatment of depression in the American market. The company... Certificate Of Practicing Company Secretary Under Regulation 40(10) Of The SEBI Listing Regulations, 2015 For The Half Year Ended On September 30, 2017.
Certificate of Practicing Company Secretary under Regulation 40(10) of the SEBI Listing Regulations, 2015 for the half year ended on September 30, 2017. Statement Of Investor Complaints For The Quarter Ended On September 30, 2017.
Statement of investor complaints for the quarter ended on September 30, 2017. Press Release / Media Release
Zydus receives final approval from the USFDA for Amitriptyline Hydrochloride Tablets USP. Cadila: Among few bright spots in pharma space
Unlike many of its pharma peers, there has been a slew of goods news for Cadila Healthcare in recent times. While its Moraiya plant recently got clearance of the US FDA, Cadila has also received almost a dozen approvals for new launches in the US since September. In the last 7-8 days itself, there were five announcements on fresh approvals for new products and dosage forms. Faster launches is crucial for the US business (40 per cent of sales), given the intense pricing pressure being faced by all pharma companies, and will enable Cadila to sustain its growth rates.While the approval rate remains strong, shortage of hypertension drug, Atenolol in the US can help Cadila garner some quick gains too. In the four generic player markets, the shortage of Active Pharma Ingredients (or APIs) for the drug is proving helpful for Cadila, which is not facing any shortage. Cadila's market share has surged from 16 per cent to 47 per cent (absolute increase of 130 per cent) suggests a Credit Suisse .. Press Release / Media Release
Zydus receives final approval from the USFDA for Dutasteride Capsules. Shareholding for the Period Ended September 30, 2017
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click here Zydus Cadila gets USFDA nod for overactive bladder drug
Zydus Cadila has received final approval from the US health regulator to market capsules used in treating overactive bladder with symptoms such as urinary frequency. The company has received... Press Release / Media Release
'Zydus receives final approval from the USFDA for Fesoterodine Fumarate Extended-Release Tablets' Press Release / Media Release
Zydus receives final approval from the USFDA for Desmopressin Nasal Spray Solution USP